Makes you wonder if our partners AstraZeneca should look at adding our DEP technology to their COVID-19 nasal spray vaccine - would our DEP technology increase antibody responses / vaccine absorption in patients I wonder ?
https://thehill.com/policy/healthca...fails-to-offer-desired-protection-in-testing/
Nasal COVID spray fails to offer desired protection in testing
A recent clinical trial has found less-than-promising results for a nasally administered version of AstraZeneca’s COVID-19 vaccine, with immune responses only observed in “a minority of participants.”
University of Oxford researchers found in their Phase 1 clinical trial that not only were antibody responses only seen in a minority of participants, but these responses were also weaker in comparison to intramuscular vaccinations. The nasal formula that was administered was the same one used for intramuscular injections.
- Forums
- ASX - By Stock
- SPL
- Ann: VIRALEZE relaunched by LloydsPharmacy in the UK
Ann: VIRALEZE relaunched by LloydsPharmacy in the UK, page-240
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.5¢ |
Change
0.004(4.40%) |
Mkt cap ! $38.76M |
Open | High | Low | Value | Volume |
9.2¢ | 9.5¢ | 9.2¢ | $60.35K | 644.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 61597 | 9.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.6¢ | 7645 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 61597 | 0.094 |
2 | 126688 | 0.092 |
2 | 123413 | 0.091 |
4 | 122750 | 0.090 |
2 | 97420 | 0.089 |
Price($) | Vol. | No. |
---|---|---|
0.096 | 7645 | 2 |
0.099 | 8240 | 3 |
0.100 | 115181 | 5 |
0.105 | 66531 | 3 |
0.110 | 16500 | 2 |
Last trade - 14.04pm 26/08/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |